30 results on '"Paganelli, Giovanni"'
Search Results
2. Development of sentinel node localization and ROLL in breast cancer in Europe
- Author
-
Paganelli, Giovanni, Luini, Alberto, Sansovini, Maddalena, Caroli, Paola, and Matteucci, Federica
- Published
- 2015
- Full Text
- View/download PDF
3. Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy
- Author
-
Gilardi, Laura, De Cicco, Concetta, Colleoni, Marco, Cardillo, Anna, Montagna, Emilia, Dellapasqua, Silvia, Galimberti, Viviana, Bagnardi, Vincenzo, and Paganelli, Giovanni
- Published
- 2010
- Full Text
- View/download PDF
4. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with 90Y-labeled biotin
- Author
-
Paganelli, Giovanni, De Cicco, Concetta, Ferrari, Mahila E., Carbone, Giuseppe, Pagani, Gianmatteo, Leonardi, Maria Cristina, Cremonesi, Marta, Ferrari, Annamaria, Pacifici, Monica, Di Dia, Amalia, De Santis, Rita, Galimberti, Viviana, Luini, Alberto, Orecchia, Roberto, Zurrida, Stefano, and Veronesi, Umberto
- Published
- 2010
- Full Text
- View/download PDF
5. Sentinel lymph node biopsy in pregnant patients with breast cancer
- Author
-
Gentilini, Oreste, Cremonesi, Marta, Toesca, Antonio, Colombo, Nicola, Peccatori, Fedro, Sironi, Roberto, Sangalli, Claudia, Rotmensz, Nicole, Pedroli, Guido, Viale, Giuseppe, Veronesi, Paolo, Galimberti, Viviana, Goldhirsch, Aron, Veronesi, Umberto, and Paganelli, Giovanni
- Published
- 2010
- Full Text
- View/download PDF
6. Sentinel node in breast cancer procedural guidelines
- Author
-
Buscombe, John, Paganelli, Giovanni, Burak, Zeynep E., Waddington, Wendy, Maublant, Jean, Prats, Enrique, Palmedo, Holger, Schillaci, Orazio, Maffioli, Lorenzo, Lassmann, M., Chiesa, Carlo, Bombardieri, Emilio, Chiti, Arturo, and On behalf of the European Association of Nuclear Medicine Oncology Committee and Dosimetry Committee
- Published
- 2007
- Full Text
- View/download PDF
7. Occult Breast Lesion Localization plus Sentinel Node Biopsy (SNOLL): Experience with 959 Patients at the European Institute of Oncology
- Author
-
Monti, Simonetta, Galimberti, Viviana, Trifiro, Giuseppe, De Cicco, Concetta, Peradze, Nicolas, Brenelli, Fabricio, Fernandez-Rodriguez, Julia, Rotmensz, Nicole, Latronico, Antuono, Berrettini, Anastasio, Mauri, Manuela, Machado, Leonidas, Luini, Alberto, and Paganelli, Giovanni
- Published
- 2007
- Full Text
- View/download PDF
8. Second Biopsy of Axillary Sentinel Lymph Node for Reappearing Breast Cancer After Previous Sentinel Lymph Node Biopsy
- Author
-
Intra, Mattia, Trifirò, Giuseppe, Viale, Giuseppe, Rotmensz, Nicole, Gentilini, Oreste D., Soteldo, Javier, Galimberti, Viviana, Veronesi, Paolo, Luini, Alberto, Paganelli, Giovanni, and Veronesi, Umberto
- Published
- 2005
- Full Text
- View/download PDF
9. Sentinel node detection in pre-operative axillary staging
- Author
-
Trifirò, Giuseppe, Viale, Giuseppe, Gentilini, Oreste, Travaini, Laura Lavinia, and Paganelli, Giovanni
- Published
- 2004
- Full Text
- View/download PDF
10. Sentinel Lymph Node Metastasis in Microinvasive Breast Cancer
- Author
-
Intra, Mattia, Zurrida, Stefano, Maffini, Fausto, Sonzogni, Angelica, Trifirò, Giuseppe, Gennari, Roberto, Arnone, Paolo, Bassani, Guillermo, Opazo, Antonio, Paganelli, Giovanni, Viale, Giuseppe, and Veronesi, Umberto
- Published
- 2003
- Full Text
- View/download PDF
11. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
- Author
-
Veronesi, Umberto, Paganelli, Giovanni, Galimberti, Viviana, Viale, Giuseppe, Zurrida, Stefano, Bedoni, Marilia, Costa, Alberto, De Cicco, Concetta, Geraghty, James G., Luini, Alberto, Sacchini, Virgilio, and Veronesi, Paolo
- Subjects
Breast cancer ,Lymph nodes -- Medical examination ,Axilla - Published
- 1997
12. Exploratory Analysis of 18F-3'-deoxy-3'-fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
- Author
-
Fantini, Lorenzo, Belli, Maria Luisa, Azzali, Irene, Loi, Emiliano, Bettinelli, Andrea, Feliciani, Giacomo, Mezzenga, Emilio, Fedeli, Anna, Asioli, Silvia, Paganelli, Giovanni, Sarnelli, Anna, and Matteucci, Federica
- Subjects
NEOADJUVANT chemotherapy ,RADIOMICS ,BREAST cancer - Abstract
Purpose: The objective of this study was to evaluate a set of radiomics-based advanced textural features extracted from
18 F-FLT-PET/CT images to predict tumor response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (BC). Materials and Methods: Patients with operable (T2-T3, N0-N2, M0) or locally advanced (T4, N0-N2, M0) BC were enrolled. All patients underwent chemotherapy (six cycles every 3 weeks). Surgery was performed within 4 weeks of the end of NCT. The MD Anderson Residual Cancer Burden calculator was used to evaluate the pathological response.18 F-FLT-PET/CT was performed 2 weeks before the start of NCT and approximately 3 weeks after the first cycle. The evaluation of PET response was based on EORTC criteria. Standard uptake value (SUV) statistics (SUVmax , SUVpeak , SUVmean ), together with 148 textural features, were extracted from each lesion. Indices that are robust against contour variability (ICC test) were used as independent variables to logistically model tumor response. LASSO analysis was used for variable selection. Results: Twenty patients were included in the study. Lesions from 15 patients were evaluable and analyzed: 9 with pathological complete response (pCR) and 6 with pathological partial response (pPR). Concordance between PET response and histological examination was found in 13/15 patients. LASSO logistic modelling identified a combination of SUVmax and the textural feature index IVH_VolumeIntFract_90 as the most useful to classify PET response, and a combination of PET response, ID range, and ID_Coefficient of Variation as the most useful to classify pathological response. Conclusions: Our study suggests the potential usefulness of FLT-PET for early monitoring of response to NCT. A model based on PET radiomic characteristics could have good discriminatory capacity of early response before the end of treatment. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT
- Author
-
Gilardi, Laura, Vassallo, Stefano, Colandrea, Marzia, Travaini, Laura Lavinia, and Paganelli, Giovanni
- Subjects
18F-FDG ,Spinal cord metastases ,Cancer Research ,Breast cancer ,Oncology ,PET/CT ,NO - Published
- 2013
14. Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?
- Author
-
De Cicco, Concetta, Gilardi, Laura, Botteri, Edoardo, Fracassi, Silvia L.V., Di Dia, Giuseppina A., Botta, Francesca, Prisco, Gennaro, Lombardo, Dario, Rotmensz, Nicole, Veronesi, Umberto, and Paganelli, Giovanni
- Subjects
BREAST cancer ,GLUCOSE ,FOLLOW-up studies (Medicine) ,UNIVARIATE analysis ,POSITRON emission tomography ,CANCER tomography - Abstract
Abstract: Background: We retrospectively investigated
18 F-FDG uptake by the primary breast tumor as a predictor for relapse and survival. Patients and methods: We studied 203 patients with cT1-T3N0 breast cancer. Standardized uptake value (SUVmax), was measured on the primary tumor. After a median follow-up of 68 months (range 22–80), the relation between SUVmax and tumor factors, disease free-survival (DFS) and overall survival (OS) was investigated. Results: In the PET-positive patients, the median FDG uptake by the tumor was 4.7. FDG uptake was significantly related to tumor size, number of involved axillary nodes, grade, negative ER, high Ki-67 and HER2 overexpression. No distant metastases or deaths occurred in the PET-negative group. Five-year DFS was 97% and 83%, respectively in the PET-negative and PET-positive groups (P = 0.096). At univariate analysis, DFS was significantly lower in patients with SUVmax >4.7 compared to the patients with negative PET (P = 0.042), but not to the patients with SUVmax ≤4.7 (P = 0.106). At multivariable analysis, among PET-positive patients, SUVmax was not an independent prognostic factor for DFS (HR>4.7 vs ≤4.7 : 1.02 (95% CI 0.45–2.31)). Five-year OS was 100% and 93%, respectively, in the PET-negative and PET-positive groups (P = 0.126). Conclusion: FDG uptake by the primary lesion was significantly associated with several prognostic variables, but it was not an independent prognostic factor. [Copyright &y& Elsevier]- Published
- 2013
- Full Text
- View/download PDF
15. Investigation of F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.
- Author
-
Gilardi, Laura, De Cicco, Concetta, Colleoni, Marco, Cardillo, Anna, Montagna, Emilia, Dellapasqua, Silvia, Galimberti, Viviana, Bagnardi, Vincenzo, and Paganelli, Giovanni
- Subjects
POSITRON emission tomography ,CANCER patients ,BREAST cancer treatment ,CANCER invasiveness ,DIAGNOSTIC imaging - Abstract
Purpose: The main objective of this study was to determine the role of [F]-2-fluoro-2-deoxy- D-glucose positron emission tomography (FDG PET) in the selection of patients with breast cancer as candidates for sentinel node biopsy (SNB) after neoadjuvant therapy. Methods: Forty-four patients with primary breast cancer clinically classified as cT2, cT3 or cT4 cN0-N2 or cN3 M0 and with a baseline FDG PET scan positive both in the site of primary tumour and axillary lymph nodes underwent neoadjuvant therapy and then a second FDG PET scan. In the case of axillary FDG PET uptake, patients underwent axillary lymph node dissection (ALND). If the second FDG PET scan was negative for axillary involvement, SNB was performed in order to evaluate axillary lymph node status. Only in the case of SN positivity did total ALND follow. Results: Specificity and positive predictive value of FDG PET for detection of axillary lymph node metastases after neoadjuvant therapy were as high as 83% (95% confidence interval: 51–97%) and 85% (95% confidence interval: 54–97%), respectively, whereas sensitivity, negative predictive value and diagnostic accuracy were inadequate for a correct staging (34, 32 and 48%, respectively). Conclusion: The poor sensitivity of FDG PET in detecting axillary lymph node metastases makes SNB mandatory in cases of a negative scan. The relatively high positive predictive value seems to suggest a role of FDG PET in selecting patients who, after neoadjuvant therapy, are candidates for ALND, avoiding SNB. However, this issue requires confirmation in a larger series of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma.
- Author
-
Trifirò, Giuseppe, Travaini, Laura L., Sanvito, Francesca, Pacifici, Monica, Mallia, Andrew, Ferrari, Mahila E., Vertua, Andrea, Maggioni, Angelo, Paganelli, Giovanni, and Sideri, Mario G.
- Subjects
MELANOMA ,SENTINEL lymph nodes ,SURGICAL excision ,BREAST cancer ,METASTASIS ,ONCOLOGIC surgery ,PATIENTS - Abstract
Vulvar melanoma is a rare malignant tumour. Its surgical excision is the mainstay of treatment whilst the surgical management of regional lymph nodes remains controversial; on the contrary elective inguinofemoral lymphadenectomy causes considerable morbidity. Lymphoscintigraphy (LS) and sentinel lymph node biopsy (SLNB) are accurate staging procedures of lymph node status in breast cancer and cutaneous melanoma patients. In this retrospective paper we report our experience of LS and SLNB in vulvar melanoma patients. Twenty-two consecutive patients with a diagnosis of vulvar melanoma were treated at our institute: patients with clinically positive groin nodes or with previous surgery on the primary tumour were excluded. Twelve were selected for our analysis. All patients underwent sentinel lymph node localization with LS the day before surgery and the surgical procedure of SLNB associated with radical surgery. Six patients had metastatic SLNB and in five of six (83.3%) it was the only positive node. In the other six patients SLNB was negative for metastatic disease. No skip metastases were observed. In SLNB negative patients the mean Breslow thickness was 2.06 mm (range: 0.60–7.10) and only one patient showed a high Breslow thickness (patient 8). In SLNB positive patients the mean Breslow thickness was 4.33 mm (1.8–6.0). Our data indicate that, even in vulvar melanoma, the sentinel lymph node pathological status predicts the pathological status of the remaining groin nodes and suggests that elective groin dissection can be spared in cases of a negative SLNB. Breslow thickness (<1 mm) was not predictive of negative nodes. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
17. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with 90Y-labeled biotin.
- Author
-
Paganelli, Giovanni, De Cicco, Concetta, Ferrari, Mahila E., Carbone, Giuseppe, Pagani, Gianmatteo, Leonardi, Maria Cristina, Cremonesi, Marta, Ferrari, Annamaria, Pacifici, Monica, Di Dia, Amalia, De Santis, Rita, Galimberti, Viviana, Luini, Alberto, Orecchia, Roberto, Zurrida, Stefano, and Veronesi, Umberto
- Subjects
- *
RADIOISOTOPES , *BIOTIN , *AVIDIN , *IRRADIATION , *BREAST surgery - Abstract
External beam radiotherapy (EBRT) after conservative surgery for early breast cancer requires 5–7 weeks. For elderly patients and those distant from an RT center, attending for EBRT may be difficult or impossible. We investigated local toxicity, cosmetic outcomes, and quality of life in a new breast irradiation technique—intraoperative avidination for radionuclide therapy (IART)—in which avidin is administered to the tumor bed and 90Y-labelled biotin later administered intravenously to bind the avidin and provide irradiation. Reduced duration EBRT (40 Gy) is given subsequently. After surgery, 50 (ten patients), 100 (15 patients) or 150 mg (ten patients) of avidin was injected into the tumor bed. After 12-24 h, 3.7 GBq 90Y-biotin (beta source for therapeutic effect) plus 185 MBq 111In-biotin (gamma source for imaging and dosimetry) was infused slowly. Whole-body scintigraphy and SPECT/CT images were taken for up to 30 h. Shortened EBRT started 4 weeks later. Local toxicity was assessed by RTOG scale; quality of life was assessed by EORTC QOL-30. Of 35 patients recruited (mean age 63 years; range 42–74) 32 received IART plus EBRT. 100 mg avidin provided 19.5 ± 4.0 Gy to the tumor bed and was considered the optimum dose. No side-effects of avidin or 90Y-biotin occurred, with no hematological or local toxicity. Local G3 toxicity occurred in 3/32 patients during EBRT. IART plus EBRT was well accepted, with good cosmetic outcomes and maintained quality of life. IART plus reduced EBRT can accelerate irradiation after conservative breast surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
18. Contralateral or bilateral lymph drainage revealed by breast lymphoscintigraphy.
- Author
-
Trifirò, Giuseppe, Ravasi, Laura, and Paganelli, Giovanni
- Subjects
BIOPSY ,BREAST cancer ,CANCER treatment ,OPERATIVE surgery ,MEDICAL informatics - Abstract
The authors reflect on the usefulness and accuracy of sentinel lymph node biopsy (SLNB) in detecting the staging procedure in breast cancer patients. They explain that the said procedure is preferred and commonly practiced by most surgeons for breast cancer treatment. They also emphasize the importance of keeping medical records of the patients for further disease monitoring used. They believe that the SLN approach is an effective treatment procedure for breast cancer.
- Published
- 2008
- Full Text
- View/download PDF
19. The sentinel node biopsy under local anesthesia in breast cancer: Advantages and problems, how the technique influenced the activity of a breast surgery department; update from the European Institute of Oncology with more than 1000 cases.
- Author
-
Luini, Alberto, Caldarella, Pietro, Gatti, Giovanna, Veronesi, Paolo, Vento, Anna Rita, Naninato, Paola, Arnone, Paolo, Sangalli, Claudia, Brenelli, Fabricio, Sosnovskikh, Irina, Peradze, Nicholas, Dussan Luberth, Carlos Alberto, Viale, Giuseppe, and Paganelli, Giovanni
- Subjects
LYMPH nodes ,BIOPSY ,QUALITY of life ,BREAST cancer ,BREAST cancer surgery - Abstract
Summary: Sentinel lymph node biopsy (SLNB) is a staging technique with a significant impact on patients’ quality of life: the oncological effectiveness in a large number of patients affected by breast carcinoma has been already demonstrated, and the clinical research is now focusing on new indication for the biopsy and widespread adoption of the technique. At the European Institute of Oncology we are applying SLNB under local anesthesia: our aim is to improve the management of the disease with low costs for the structure and patients, and to improve patients’ acceptance of breast cancer treatments. We are now discussing the impact of the SLNB under local anesthesia on the activity of a breast surgery department. We also present an update of our experience. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
20. Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy response.
- Author
-
Travaini, Laura Lavinia, Baio, Silvia Melania, Cremonesi, Marta, Cicco, Concetta De, Ferrari, Mahila, Trifirò, Giuseppe, Prisco, Gennaro, Viale, Giuseppe, Colleoni, Marco Angelo, Radice, Davide, Sivolapenko, Gregory B., and Paganelli, Giovanni
- Subjects
BREAST cancer ,CANCER treatment ,CANCER patients ,BREAST tumors ,TUMORS - Abstract
Summary: Mammoscintigraphy (MMS) has been indicated as a useful tool in predicting response to therapy in cancer. However, contrasting results have been reported in the literature for breast cancer patients. The aim of this study was to explore the role of MMS in locally advanced breast cancer (LABC) patients. Fifty-one patients affected by LABC and scheduled for neoadjuvant therapy were enrolled. Breast tumor status was evaluated at baseline, during therapy and at the completion of therapy by radiological techniques and by MMS. Pre-therapy (MMS1) and post-therapy MIBI (2-methoxyisobutilysonitrile) images (MMS2–3) were analyzed. MMS1 was performed in all pts, 41 carried out MMS2 and 27 had MMS3. Tumor uptake and washout in MMS1 did not show any correlation with the therapy response. The absence of any association between tumor uptake and washout with respect to therapy response suggests that MMS is not a reliable technique to predict therapy response in LABC. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
21. The evolution of the conservative approach to breast cancer.
- Author
-
Luini, Alberto, Gatti, Giovanna, Zurrida, Stefano, Talakhadze, Nina, Brenelli, Fabricio, Gilardi, Daniela, Paganelli, Giovanni, Orecchia, Roberto, Cassano, Enrico, Viale, Giuseppe, Sangalli, Claudia, Ballardini, Bettina, dos Santos, Gabriela Rosali, and Veronesi, Umberto
- Subjects
BREAST cancer surgery ,CANCER radiotherapy ,QUALITY of life ,BREAST cancer patients ,CANCER treatment - Abstract
Summary: The profound revolution that surgical treatment of breast cancer has undergone during the past 30 years has led to the progressive reduction of the extent of surgery, with less mutilation. As a consequence, quality of life has improved and women are now more motivated to follow screening programs for early diagnosis of the disease. Since conservative surgery is as effective as radical surgery, research is now focused on reducing radiotherapy. Overall, survival after breast cancer is not affected by reducing the extent of surgery, which, together with less invasive diagnostic procedures, has a good effect on patients’ quality of life. For this reason in our Institute we are now evaluating the feasibility of a reduction of the radiation field and the sensibility and sensitivity of new diagnostic approaches for axillary staging. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
22. IART®: Intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation.
- Author
-
Paganelli, Giovanni, Ferrari, Mahila, Cremonesi, Marta, De Cicco, Concetta, Galimberti, Viviana, Luini, Alberto, Veronesi, Paolo, Fiorenza, Maurizio, Carminati, Paolo, Zanna, Claudio, Orecchia, Roberto, and Veronesi, Umberto
- Subjects
RADIOISOTOPES ,BREAST cancer ,CANCER patients ,AVIDIN ,THERAPEUTICS ,TUMORS ,RADIOTHERAPY - Abstract
Summary: A new procedure, known as Intraoperative Avidination for Radionuclide Therapy (IART
® ), is described in breast cancer patients. In this paper, we provide proof of the principle that intraoperative injection of avidin in the tumour bed after quadrantectomy allows homing in of intravenously (IV) administered radioactive biotin to the target site. This approach of targeted therapy consists of two steps: [(i)] “avidination” of the anatomical area of the tumour with avidin injected by the surgeon, into and around the tumour bed; [(ii)] targeting the anatomical area of the tumour by IV injection of radiolabelled biotin. The scintigraphic images demonstrated fast and stable uptake of labelled biotin at the site of operated breast. The radiation dose released to the index quadrant was more than 5Gy/GBq, consistent with a boost of 20Gy for an activity of 3.7GBq90 Y-biotin (100mCi). A further large clinical trial facing IART® in combination with reduced external-beam radiotherapy is, in our opinion, fully justified. [Copyright &y& Elsevier]- Published
- 2007
- Full Text
- View/download PDF
23. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study
- Author
-
Veronesi, Umberto, Paganelli, Giovanni, Viale, Giuseppe, Luini, Alberto, Zurrida, Stefano, Galimberti, Viviana, Intra, Mattia, Veronesi, Paolo, Maisonneuve, Patrick, Gatti, Giovanna, Mazzarol, Giovanni, De Cicco, Concetta, Manfredi, Gianfranco, and Fernández, Julia Rodríguez
- Subjects
- *
BREAST cancer , *CANCER in women , *CANCER patients , *CANCER invasiveness , *LYMPH nodes - Abstract
Summary: Background: In women with breast cancer, sentinel-lymph-node biopsy (SLNB) provides information that allows surgeons to avoid axillary-lymph-node dissection (ALND) if the SLN does not have metastasis, and has a favourable effect on quality of life. Results of our previous trial showed that SLNB accurately screens the ALN for metastasis in breast cancers of diameter 2 mm or less. We aimed to update this trial with results from longer follow-up. Methods: Women with breast tumours of diameter 2 cm or less were randomly assigned after breast-conserving surgery either to SLNB and total ALND (ALND group), or to SLNB followed by ALND only if the SLN was involved (SLN group). Analysis was restricted to patients whose tumour characteristics met eligibility criteria after treatment. The main endpoints were the number of axillary metastases in women in the SLN group with negative SLNs, staging power of SLNB, and disease-free and overall survival. Findings: Of the 257 patients in the ALND group, 83 (32%) had a positive SLN and 174 (68%) had a negative SLN; eight of those with negative SLNs were found to have false-negative SLNs. Of the 259 patients in the SLN group, 92 (36%) had a positive SLN, and 167 (65%) had a negative SLN. One case of overt clinical axillary metastasis was seen in the follow-up of the 167 women in the SLN group who did not receive ALND (ie, one false-negative). After a median follow-up of 79 months (range 15–97), 34 events associated with breast cancer occurred: 18 in the ALND group, and 16 in the SLN group (log-rank p=0·6). The overall 5-year survival of all patients was 96·4% (95% CI 94·1–98·7) in the ALND group and 98·4% (96·9–100) in the SLN group (log-rank p=0·1). Interpretation: SLNB can allow total ALND to be avoided in patients with negative SLNs, while reducing postoperative morbidity and the costs of hospital stay. The finding that only one overt axillary metastasis occurred during follow-up of patients who did not receive ALND (whereas eight cases were expected) could be explained by various hypotheses, including those from cancer-stem-cell research. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
24. Sentinel nodes scintigraphy of the internal mammary chain in breast cancer
- Author
-
Paganelli, Giovanni, Viale, Giuseppe, and Veronesi, Umberto
- Subjects
- *
BREAST cancer , *LYMPH - Abstract
Internal mammary chain lymphnodes (IMNs) were studied by lymphoscintigraphy and biopsy in 100 breast cancer patients to assess:(i) if a deep injection can visualize the IMNs in a high percentage of cases(ii) to determine how often IMNs are metastatic.More than 60% of patients showed IMNs uptake. Surgical sampling proved simple and risks insignificant. Five positive IMN cases migrated from NO/N1 to N3, prompting treatment modification. It is unclear whether this additional information can lead to better survival. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
25. PET/CT and breast cancer subtypes.
- Author
-
Gilardi, Laura, Colleoni, Marco, and Paganelli, Giovanni
- Subjects
BREAST cancer ,HORMONE receptors ,CANCER chemotherapy - Abstract
An introduction is presented in which the editors discuss various reports within the issue on topics including the correlation between glycolytic characteristics of primary breast tumors and their subtypes, the assessment of hormone receptors in multicentre study, and the response of primary tumors to neoadjuvant chemotherapy.
- Published
- 2013
- Full Text
- View/download PDF
26. Sentinel node biopsy: role of nuclear medicine in conservative surgery of breast cancer.
- Author
-
Paganelli, Giovanni
- Subjects
- *
BIOPSY , *BREAST cancer , *TUMORS , *METASTASIS - Abstract
Discusses the application of sentinel node biopsy on the diagnosis of breast cancer cells. Importance of the spread of tumor cells to axillary lymph nodes in the prognosis and therapy options in patients with breast cancer; Role of tumor size to the risk of metastases; Results of a study on the resection of sentinel nodes in breast cancer.
- Published
- 1998
- Full Text
- View/download PDF
27. A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer.
- Author
-
Veronesi, Umberto, Paganelli, Giovanni, Viale, Giuseppe, Luini, Alberto, Zurrida, Stefano, Galimberti, Viviana, Intra, Mattia, Veronesi, Paolo, Robertson, Chris, Maisonneuve, Patrick, Renne, Giuseppe, De Cicco, Concetta, De Lucia, Francesca, and Gennari, Roberto
- Subjects
- *
BREAST cancer , *CANCER patients , *CANCER in women , *BIOPSY - Abstract
Background: Although numerous studies have shown that the status of the sentinel node is an accurate predictor of the status of the axillary nodes in breast cancer, the efficacy and safety of sentinel-node biopsy require validation. Methods: From March 1998 to December 1999, we randomly assigned 516 patients with primary breast cancer in whom the tumor was less than or equal to 2 cm in diameter either to sentinel-node biopsy and total axillary dissection (the axillary-dissection group) or to sentinel-node biopsy followed by axillary dissection only if the sentinel node contained metastases (the sentinel-node group). Results: The number of sentinel nodes found was the same in the two groups. A sentinel node was positive in 83 of the 257 patients in the axillary-dissection group (32.3 percent), and in 92 of the 259 patients in the sentinel-node group (35.5 percent). In the axillary-dissection group, the overall accuracy of the sentinel-node status was 96.9 percent, the sensitivity 91.2 percent, and the specificity 100 percent. There was less pain and better arm mobility in the patients who underwent sentinel-node biopsy only than in those who also underwent axillary dissection. There were 15 events associated with breast cancer in the axillary-dissection group and 10 such events in the sentinel-node group. Among the 167 patients who did not undergo axillary dissection, there were no cases of overt axillary metastasis during follow-up. Conclusions: Sentinel-node biopsy is a safe and accurate method of screening the axillary nodes for metastasis in women with a small breast cancer. N Engl J Med 2003;349:546-53. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
28. Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases
- Author
-
Veronesi, Umberto, Galimberti, Viviana, Paganelli, Giovanni, Maisonneuve, Patrick, Viale, Giuseppe, Orecchia, Roberto, Luini, Alberto, Intra, Mattia, Veronesi, Paolo, Caldarella, Pietro, Renne, Giuseppe, Rotmensz, Nicole, Sangalli, Claudia, De Brito Lima, Luciana, Tullii, Marco, and Zurrida, Stefano
- Subjects
- *
BREAST cancer patients , *METASTASIS , *BIOPSY , *CANCER cells , *DISSECTION , *FOLLOW-up studies (Medicine) - Abstract
Abstract: Premises: Sentinel node biopsy (SNB) in patients with breast carcinoma accurately predicts the axillary node status. However, in some 4–7% of patients with negative sentinel nodes, the remaining axillary nodes harbour cancer cells. Objective: Our purpose was the long-term observation of a large number of patients who did not receive axillary dissection after a negative sentinel node biopsy, in order to evaluate the incidence of overt axillary metastases. Methods: Patients (3548) treated from 1996 to 2004, with negative sentinel nodes not submitted to axillary dissection, were followed up to 11 years with a median follow-up of 48 months. Results: Three hundred and sixteen unfavourable events occurred among the 3548 patients, 196 of which (5.5%) related to primary breast carcinoma. Thirty one cases of overt axillary metastases were found (0.9%): they received total axillary dissection and 27 of them are at present alive and well. The 5-year overall survival rate of the whole series was 98%. Conclusions: Patients with negative sentinel node biopsy not submitted to axillary dissection show, at follow-up, a rate of overt axillary metastases lower than expected. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
29. Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection
- Author
-
Veronesi, Umberto, Galimberti, Viviana, Mariani, Luigi, Gatti, Giovanna, Paganelli, Giovanni, Viale, Giuseppe, Zurrida, Stefano, Veronesi, Paolo, Intra, Mattia, Gennari, Roberto, Rita Vento, Anna, Luini, Alberto, Tullii, Marco, Bassani, Guillermo, and Rotmensz, Nicole
- Subjects
- *
BREAST cancer , *CANCER patients , *CLINICAL pathology , *CANCER invasiveness - Abstract
Sentinel node biopsy in patients with breast carcinoma accurately predicts the axillary nodal status. However, in some 6% of patients with negative sentinel nodes the remaining axillary nodes harbour metastases. Our purpose was to observe a large number of patients who did not undergo an axillary dissection after a negative sentinel node biopsy for the appearance of overt axillary metastases. 953 patients treated from 1996 to 2000, with negative sentinel nodes not submitted to axillary dissection, were followed-up to 7 years, with a median follow-up of 38 months. Fifty-five unfavourable events occurred among the 953 patients, 37 (4%) related to the primary breast carcinoma. Three cases of overt axillary metastases were found: they received total axillary dissection and are presently alive and well. The 5 year overall survival rate of the whole series was 98%. Patients with negative sentinel node biopsies not submitted to axillary dissection show during follow-up a rate of overt axillary metastases that is lower than that expected. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
30. A Delphic consensus assessment : imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
- Author
-
Eric P. Krenning, Ashley B. Grossman, Giovanni Paganelli, Nicola Fazio, Mauro Cives, Annemeik Walenkamp, Anders Sundin, Jonathan R. Strosberg, Klaus Koopmans, Irene Virgolini, Mark Kidd, Lisa Bodei, Andreas Kjaer, Stefano Severi, Valentina Ambrosini, Robert T. Jensen, Irvin M. Modlin, Matthew H. Kulke, Dik J. Kwekkeboom, Tiny Korse, Richard P. Baum, Ramon Salazar, Marianne Pavel, Andrea Frilling, Helmut R. Maecke, Margot E T Tesselaar, Ignat Drozdov, Kjell Öberg, Jarosław B. Ćwikła, Vikas Prasad, Massimo Falconi, Aldo Scarpa, Dr. Heinz-Horst Deichmann Stiftung, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Oberg, Kjell, Krenning, Eric, Sundin, Ander, Bodei, Lisa, Kidd, Mark, Tesselaar, Margot, Ambrosini, Valentina, Baum, Richard P, Kulke, Matthew, Pavel, Marianne, Cwikla, Jaroslaw, Drozdov, Ignat, Falconi, Massimo, Fazio, Nicola, Frilling, Andrea, Jensen, Robert, Koopmans, Klau, Korse, Tiny, Kwekkeboom, Dik, Maecke, Helmut, Paganelli, Giovanni, Salazar, Ramon, Severi, Stefano, Strosberg, Jonathan, Prasad, Vika, Scarpa, Aldo, Grossman, Ashley, Walenkamp, Annemeik, Cives, Mauro, Virgolini, Irene, Kjaer, Andrea, Modlin, Irvin M, Radiology & Nuclear Medicine, Oberg, K., Krenning, E., Sundin, A., Bodei, L., Kidd, M., Tesselaar, M., Ambrosini, V., Baum, R. P., Kulke, M., Pavel, M., Cwikla, J., Drozdov, I., Falconi, M., Fazio, N., Frilling, A., Jensen, R., Koopmans, K., Korse, T., Kwekkeboom, D., Maecke, H., Paganelli, G., Salazar, R., Severi, S., Strosberg, J., Prasad, V., Scarpa, A., Grossman, A., Walenkamp, A., Cives, M., Virgolini, I., Kjaer, A., and Modlin, I. M.
- Subjects
Oncology ,carcinoid ,Pathology ,GA-68-DOTA-TYR(3)-OCTREOTIDE PET ,Endocrinology, Diabetes and Metabolism ,Computed tomography ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit ,CHROMOGRANIN-A ,Biomarker ,Carcinoid ,CT scan ,CTC ,Delphic consensus ,Imaging ,MRI ,MRNA ,Multianalyte ,NETest ,Neuroendocrine tumor ,PET ,RECIST ,Somatostatin ,Internal Medicine ,Endocrinology ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Imaging modalities ,PROGNOSTIC-FACTORS ,0302 clinical medicine ,Medicine ,Disease management (health) ,ENDOCRINE NEOPLASIA TYPE-1 ,medicine.diagnostic_test ,imaging ,Diabetes and Metabolism ,GUIDELINES UPDATE ,030220 oncology & carcinogenesis ,Endokrinologi och diabetes ,Biomarker (medicine) ,biomarker ,neuroendocrine tumor ,medicine.medical_specialty ,TRANSCRIPT ANALYSIS ,mRNA ,030209 endocrinology & metabolism ,somatostatin ,Endocrinology and Diabetes ,NO ,Delphic consensu ,03 medical and health sciences ,POSITRON-EMISSION-TOMOGRAPHY ,Breast cancer ,multianalyte ,Internal medicine ,Journal Article ,BREAST-CANCER ,Gastroenteropancreatic neuroendocrine tumor ,Neuroendocrine neoplasia ,lcsh:RC648-665 ,business.industry ,Research ,CLINICAL UTILITY ,Transcript analysis ,medicine.disease ,MEDIATED RADIONUCLIDE THERAPY ,business - Abstract
The complexity of the clinical management of neuroendocrine neoplasia (NEN) is exacerbated by limitations in imaging modalities and a paucity of clinically useful biomarkers. Limitations in currently available imaging modalities reflect difficulties in measuring an intrinsically indolent disease, resolution inadequacies and inter-/intra-facility device variability and that RECIST (Response Evaluation Criteria in Solid Tumors) criteria are not optimal for NEN. Limitations of currently used biomarkers are that they are secretory biomarkers (chromogranin A, serotonin, neuron-specific enolase and pancreastatin); monoanalyte measurements; and lack sensitivity, specificity and predictive capacity. None of them meet the NIH metrics for clinical usage. A multinational, multidisciplinary Delphi consensus meeting of NEN experts (n = 33) assessed current imaging strategies and biomarkers in NEN management. Consensus (>75%) was achieved for 78% of the 142 questions. The panel concluded that morphological imaging has a diagnostic value. However, both imaging and current single-analyte biomarkers exhibit substantial limitations in measuring the disease status and predicting the therapeutic efficacy. RECIST remains suboptimal as a metric. A critical unmet need is the development of a clinico-biological tool to provide enhanced information regarding precise disease status and treatment response. The group considered that circulating RNA was better than current general NEN biomarkers and preliminary clinical data were considered promising. It was resolved that circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis and monitoring disease status and therapeutic efficacy. Overall, it was concluded that a combination of tumor spatial and functional imaging with circulating transcripts (mRNA) would represent the future strategy for real-time monitoring of disease progress and therapeutic efficacy.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.